Taysha Gene Therapies (TSHA) Payables (2020 - 2026)
Taysha Gene Therapies (TSHA) posted Payables of $4.6 million for Q1 2026, down 27.27% sequentially from $6.3 million in Q4 2025, and up 5.5% YoY from $4.3 million in Q1 2025.
Taysha Gene Therapies (TSHA) Payables (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has reported Payables for 7 years, with the latest figure at $4.6 million in Q1 2026.
- Quarterly Payables rose 5.5% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.6 million (up 5.5% YoY) and the FY2025 annual result came in at $6.3 million, up 74.69% from the prior year.
- Payables declined to $4.6 million in Q1 2026 per TSHA's latest filing, from $6.3 million in the prior quarter.
- Over five years, Payables peaked at $148.1 million in Q3 2023 and troughed at $3.6 million in Q4 2024.
- A 5-year average of $17.8 million and a median of $8.7 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2023 and 2024: Payables jumped 870.78% in 2023, then plunged 96.67% in 2024.
- Over 5 years, Payables stood at $10.9 million in 2022, then plunged by 41.84% to $6.4 million in 2023, then plunged by 43.58% to $3.6 million in 2024, then surged by 74.69% to $6.3 million in 2025, then dropped by 27.27% to $4.6 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $4.6 million, $6.3 million, and $5.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Taysha Gene Therapies | 1.94 Bn | 1.94 Bn | - | 9.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.16 Mn |
| Mar 31, 2026 | 4.56 Mn |
| Dec 31, 2025 | 6.28 Mn |
| Sep 30, 2025 | 5.44 Mn |
| Jun 30, 2025 | 7.71 Mn |
| Mar 31, 2025 | 4.33 Mn |
| Dec 31, 2024 | 3.59 Mn |
| Sep 30, 2024 | 4.93 Mn |
| Jun 30, 2024 | 8.72 Mn |
| Mar 31, 2024 | 10.38 Mn |
| Dec 31, 2023 | 6.37 Mn |
| Sep 30, 2023 | 148.05 Mn |
| Jun 30, 2023 | 10.77 Mn |
| Mar 31, 2023 | 9.00 Mn |
| Dec 31, 2022 | 10.95 Mn |
| Sep 30, 2022 | 15.25 Mn |
| Jun 30, 2022 | 23.97 Mn |
| Mar 31, 2022 | 22.00 Mn |
| Dec 31, 2021 | 21.76 Mn |
| Sep 30, 2021 | 22.05 Mn |